Apollomics Is A Clinical Stage Biopharmaceutical Company Focused On Developing Innovative Oncology Therapiesthe Company Aims To Enhance Treatment Options For Patients With Challenging Cancers That Have High Mortality Rateswith A Presence In Both The U Sand Chinaapollomics Fosters Partnerships With Biotechnology Firms From Both Regionsfacilitating Access To Global Markets The Company Specializes In The Discovery And Development Of Various Oncology Therapiesincluding Tumor Inhibitors That Target Cancer Cell Growth Pathwaysanti Cancer Enhancers That Improve Chemotherapy Efficacyand Immuno Oncology Drugs That Utilize The Immune System To Combat Cancerapollomics Has A Robust Pipeline Featuring Nine Novel Drug Candidatessix Of Which Are Currently In Clinical Developmenttargeting Cancers Such As Lung Cancerbrain Cancerand Acute Myeloid Leukemia Apollomics Has Secured Significant Funding To Support Its Clinical Programs And Has Established Operational Bases In Both The U Sand Chinawith Offices And Laboratories In Hangzhou And Shanghaithis Strategic Setup Allows The Company To Integrate In House Innovations With External Collaborations To Advance Cancer Therapies For Both Domestic And International Markets
